Pfizer’s new cost-saving agenda will see five pipeline programs in oncology, rare disease and immunology packed off to the graveyard.Three of the terminated programs are phase 1 oncology assets, according to Pfizer’s online product pipeline, which was updated on October 31. First up in the discard pile is PF-06647020, a non-small-cell lung cancer (NSCLC) biologic […]
